Checkpoint Capital’s Disc Medicine IRON Stock Holding History

Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake
Trade Value Portfolio Weight Portfolio Position
2026
Q2
$17.6M Sell
240,125
-46,536
-16% -$3.2M 4.51% 5
2026
Q1
$18.3M Sell
286,661
-166,331
-37% -$11.5M 6.58% 4
2025
Q4
$36M Buy
452,992
+22,992
+5% +$1.94M 11.24% 3
2025
Q3
$28.4M Buy
430,000
+165,000
+62% +$9.82M 9.52% 4
2025
Q2
$14M Buy
265,000
+21,689
+9% +$1.02M 6.54% 4
2025
Q1
$12.1M Buy
243,311
+58,311
+32% +$3.24M 6.63% 5
2024
Q4
$11.7M Buy
185,000
+159,457
+624% +$9.22M 5.97% 5
2024
Q3
$1.26M Buy
+25,543
New +$1.2M 0.62% 14
2024
Q1
– Sell
-10,000
Closed -$578K – 20
2023
Q4
$578K Buy
+10,000
New +$512K 0.35% 17

Other funds holding IRON

Checkpoint Capital's IRON Position: Q2 2026 in Review

Checkpoint Capital reduced its Disc Medicine (IRON) stake by 16% in Q2 2026, selling an estimated $3.2M and leaving 240,125 shares worth $17.6M. The position accounts for 4.51% of the portfolio, ranked #5.

Checkpoint Capital first reported a position in IRON in Q4 2023 and has held it in 9 quarters since. The position peaked at $36M in Q4 2025. 216 funds tracked by Wall St. Rank hold IRON as of Q2 2026.

  • Checkpoint Capital held 240,125 shares of Disc Medicine worth $17.6M as of Q2 2026.
  • Checkpoint Capital sold 46,536 Disc Medicine shares in Q2 2026, an estimated $3.2M.
  • Disc Medicine made up 4.51% of Checkpoint Capital's portfolio in Q2 2026, its #5 holding.
  • Checkpoint Capital first reported a position in Disc Medicine in Q4 2023 and has held it in 9 quarters since.
  • Checkpoint Capital's Disc Medicine position peaked at $36M in Q4 2025.
  • 216 funds tracked by Wall St. Rank held Disc Medicine as of Q2 2026.

Based on Checkpoint Capital's 13F filing for Q2 2026, filed 14 Aug 2026.